Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (FIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04908228
Recruitment Status : Recruiting
First Posted : June 1, 2021
Last Update Posted : April 11, 2022
Information provided by (Responsible Party):
Paolo Ghia, IRCCS San Raffaele

Brief Summary:

This is a phase 2 multicenter national interventional pharmacological study aimed at determining the efficacy of a fixed duration treatment with ibrutinib and obinutuzumab in terms of uMRD in the BM at the end of treatment (+30 Days follow-up).

Treatment with ibrutinib and obinutuzumab will be administered according to the following schedule:

Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).

At the end of Cycle 24 all responding patients will discontinue ibrutinib and proceed with follow-up. If disease relapse occurs at any time after discontinuing treatment, ibrutinib therapy will be reintroduced at the standard dose of 420 mg QD and response to treatment monitored over time. Patients with stable (SD) or progressive disease (PD) at the end of Cycle 24, will continue ibrutinib as long as the treating physician deems they are benefiting from treatment and will be followed up in the study for survival and response to subsequent therapies.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: Ibrutinib and obinutuzumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
Actual Study Start Date : December 13, 2021
Estimated Primary Completion Date : September 15, 2022
Estimated Study Completion Date : September 15, 2027

Arm Intervention/treatment
Experimental: Ibrutinib + obinutuzumab
Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).
Drug: Ibrutinib and obinutuzumab
Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
Other Name: Imbruvica and Gazyvaro

Primary Outcome Measures :
  1. BM MRD <10-4 at 30 days follow-up [ Time Frame: 24 months ]
    To evaluate the rate of bone marrow minimal residual disease <10-4 at +30 Days follow-up after ibrutinib and obinutuzumab

Secondary Outcome Measures :
  1. Overall response rate at 30 days follow-up [ Time Frame: 24 months ]
    To evaluate response to treatment after ibrutinib and obinutuzumab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 years
  2. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets iwCLL diagnostic criteria
  3. Previously untreated active disease requiring treatment per iwCLL criteria
  4. ECOG PS 0 or 1
  5. Measurable lymph node disease (>1.5 cm longest diameter) by CT scan
  6. Adequate hematologic function defined as:

    1. Absolute neutrophil count (ANC) >750 cells/μL (750 cells/mm3 or 0.75 x 109/L)
    2. Platelet count >30,000/μL (30,000 cells/mm3 or 30 x 109/L)
    3. Hemoglobin >8.0 g/dL
  7. Adequate hepatic and renal function defined as:

    1. Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0 x upper limit of normal (ULN)
    2. Estimated Creatinine Clearance (CrCl) ≥30 mL/min (Cockcroft- Gault)
    3. Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
  8. Prothrombin time (PT)/International normal ratio (INR) <1.5 x ULN and PTT (activated partial thromboplastin time [aPTT]) <1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder).

Exclusion Criteria:

Any prior therapy (including but not limited to chemotherapy, targeted therapy, immunomodulating therapy, radiotherapy, and/or monoclonal antibody) used for treatment of CLL or SLL.

2. Patients carrying del(17p) and/or TP53 mutation as assessed by central laboratory.

3. History of other malignancies, except:

  1. Malignancy treated with curative intent and with no known active disease present for ≥3 before the first dose of study drug and felt to be at low risk for recurrence by the treating physician
  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  3. Adequately treated carcinoma in situ without evidence of disease. 4. Known or suspected history of Richter's transformation. 5. Known hypersensitivity to one or more study drugs. 6. Known bleeding disorders (eg, von Willebrand's disease or hemophilia). 7. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

    8. Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrolment. Those who are PCR positive will be excluded. 9. Unable to swallow capsules/tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.

    10. Concomitant use of warfarin or other vitamin K antagonists. 11. Major surgery within 4 weeks of first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04908228

Layout table for location contacts
Contact: Paolo Ghia, MD, PhD +39022643 ext 4797
Contact: Eloise Scarano, PhD +39022643 ext 3919

Layout table for location information
Strategic Research Program on CLL Recruiting
Milano, MI, Italy, 20132
Contact: Paolo Ghia, MD PhD    +39022643 ext 3919   
Sponsors and Collaborators
Paolo Ghia
Layout table for additonal information
Responsible Party: Paolo Ghia, Prof, IRCCS San Raffaele Identifier: NCT04908228    
Other Study ID Numbers: PS-CLL-008
First Posted: June 1, 2021    Key Record Dates
Last Update Posted: April 11, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents, Immunological
Antineoplastic Agents